Table 1.

Characteristics of the NSCLC Cell Lines Used in this Study with EGFR and KRAS Mutational Status, Gefitinib IC50, and Gene Expression Classification of Gefitinib Sensitivity

Cell lineHistologyEGFRKRASIC50 (μmol/L)Gene prediction
(A) NSCLC lines comprising the training set
    H358BACWild-typeMutant0.18Sensitive
    H322CBACWild-typeWild-type0.25Sensitive
    Calu-3AdenocarcinomaWild-typeND0.3Sensitive
    H1334LargeWild-typeWild-type0.3Sensitive
    H1648AdenocarcinomaWild-typeWild-type0.38Sensitive
    H125AdenosquamousWild-typeWild-type4.8Resistant
    H1703SquamousWild-typeWild-type8.0Resistant
    A549AdenocarcinomaWild-typeWild-type9.6Resistant
    H157SquamousWild-typeMutant12.8Resistant
    H460LargeWild-typeMutant12.9Resistant
    H520SquamousWild-typeND13.6Resistant
(B) NSCLC lines comprising the test set
    HCC827AdenocarcinomaMutant*Wild-type0.005Sensitive
    HCC78AdenocarcinomaWild-typeWild-type0.4Sensitive
    H2126LargeWild-typeWild-type1.0Sensitive
    H1648AdenocarcinomaWild-typeWild-type1.3Sensitive
    HCC193AdenocarcinomaWild-typeWild-type1.5Sensitive
    HCC95AdenocarcinomaWild-typeWild-type1.9Sensitive
    HCC44AdenocarcinomaWild-typeMutant7.9Resistant
    H460LargeWild-typeMutant8.0Resistant
    H2009AdenocarcinomaWild-typeMutant8.8Sensitive
    HCC15SquamousWild-typeWild-type9.4Resistant
    H157SquamousWild-typeMutant13.8Resistant
    H1299LargeWild-typeWild-type14.7Resistant
(C) Mutant EGFR NSCLC lines
    H3255AdenocarcinomaMutantND0.015Sensitive
    HCC4006AdenocarcinomaMutant*Wild-type0.02Sensitive
    HCC2279AdenocarcinomaMutant*Wild-type0.03Resistant
    H1650AdenocarcinomaMutant*Wild-type1.0Sensitive
    H820AdenocarcinomaMutant*Wild-type3.0Sensitive
    H1975AdenocarcinomaMutant,Wild-type8.0Sensitive
  • * Activating mutation (deletion) in exon 19 of EGFR.

  • Activating mutation (L858R) in exon 21 of EGFR.

  • Escape mutation (T790M) in exon 20 of EGFR.